Nuwellis, Inc. (NUWE) Fair Value 2026

NUWE · Electromedical & Electrotherapeutic Apparatus ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.0 /10

32 fundamental signals · 4 models active

Value Trap Risk

LOW (39/100)

Quick Summary — As of 2026-07-15, Nuwellis, Inc. (NUWE) trades at $3.12, approximately 15% below CirclFi’s Bayesian DCF fair value of $3.66. QOC: 6.0/10. Value Trap Risk: 39/100 (LOW). 4/13 models active.

Key Facts

Ticker
NUWE
Price
$3.12
Quality Score
6.0/10
Value Trap Risk
39/100
Models Active
4/13
Last Updated
Strength: First Chicago suggests +120.8% upside with 24% confidence
Risk: Limited model coverage (4/13) may reduce confidence

Is Nuwellis, Inc. (NUWE) Undervalued or Overvalued in 2026?

According to CirclFi’s 4-model valuation engine, Nuwellis, Inc. (NUWE) appears undervalued as of : the median of 4 independent fair value estimates is $3.91, 25.2% above the current price of $3.12. Estimates range from $3.48 to $6.89. NUWE scores 6.0/10 on fundamental quality and 39/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Nuwellis, Inc. Stock in 2026? →

Valuation Matrix

4 Intrinsic Value Models vs. Current Price ($3.12)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Medium Conviction
 $3.66 +17.3%
First Chicago
Medium Conviction
 $6.89 +120.8%

Unlock the Full Matrix

Access 2 additional models including PWERM, FTNN Topology.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 4 Models →

Cancel anytime · No contracts · Instant access

What Is Nuwellis, Inc. (NUWE) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Nuwellis, Inc.'s intrinsic value is estimated at a composite fair value of $4.55. At a current market price of $3.12, 4 of 4 active valuation models identify upside potential, projecting an average implied return of +45.7%. Notably, First Chicago sees the most upside at +120.8% (fair value: $6.89), while PWERM is the most conservative at +11.6% ($3.48). The spread between these extremes — +109.1% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About NUWE?

4 of 13 models are currently active for NUWE. All 4 active models suggest the stock trades below fair value. The Bayesian DCF estimates NUWE's intrinsic value at $3.66, implying +17.3% upside from the current price. See which stocks rank higher →

How Does NUWE Rank in Electromedical & Electrotherapeutic Apparatus?

Among 25 Electromedical & Electrotherapeutic Apparatus stocks, NUWE ranks #18 by Quality of Company score. CirclFi's QOC score of 6.0/10 evaluates 32 fundamental signals. A score of 6.0 reflects mixed fundamentals.

Nuwellis, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is NUWE a Value Trap?

CirclFi's Value Trap algorithm assigns NUWE a score of 39/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

4 of 13 models are active for Nuwellis, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Nuwellis, Inc. is rated at 6.0/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.

The gap between the most bullish and bearish model spans +109.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every NUWE valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across NUWE's 4 active models, average confidence is 26%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Nuwellis, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Electromedical & Electrotherapeutic Apparatus Stocks Should You Also Analyze?

8 related Electromedical & Electrotherapeutic Apparatus stocks with 13-model coverage

INMDInMode Ltd.QOC 9.9ELMDElectromed, Inc.QOC 9.4LIVNLivaNova PLCQOC 9.1CNMDCONMED CorporationQOC 8.9ITGRInteger Holdings CorporationQOC 8.3MDTMedtronic plc.QOC 8.1TMDXTransMedics Group, Inc.QOC 8.0AXGNAxoGen, Inc.QOC 7.9

Read investment analysis: INMD · ELMD · LIVN · CNMD · ITGR

Frequently Asked Questions About Nuwellis, Inc.

What is Nuwellis, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Nuwellis, Inc. (NUWE) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $3.66. The Quality of Company score is 6.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is NUWE overvalued or undervalued right now?

At $3.12, 4 of 4 active models suggest NUWE may be undervalued, while 0 indicate potential overvaluation. The median of all 4 fair value estimates is $3.91, 25.2% above the current price of $3.12 — a consensus view that NUWE is undervalued. The assessment depends on which methodology best fits Nuwellis, Inc.'s business model in Electromedical & Electrotherapeutic Apparatus.

What does a Quality of Company score of 6.0 mean for NUWE?

Nuwellis, Inc.'s QOC of 6.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on NUWE?

CirclFi analyzes NUWE with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 4 of 13 are active for this stock. Read the full methodology →

Is NUWE a value trap in 2026?

Nuwellis, Inc.'s Value Trap score is 39/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 4-model valuation engine, Nuwellis, Inc. (NUWE) has a median fair value of $3.91 — 25.2% above the current price of $3.12 — as of 2026-07-15.” Source: circlfi.com/stock/NUWE/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 4 mathematical frameworks give you clarity on NUWE.

Unlock All 4 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access